Mersana Therapeutics, Inc. MRSN 深 滬
等待開盤 07-22 09:30:00 美东时间
0.3593
+0.007
+1.84%
華盛通- 最 高0.37
- 今 開0.3619
- 成交量 176.99万股
- 最 低 0.358
- 昨 收 0.3528
- 總市值 4491.25万
- 52周最高 2.83
- 市盈率 靜 --
- 換手率 1.42%
- 52周最低 0.2589
- 委 比 81.85%
- 總股本 1.25亿
- 歷史最高 29.09
- 量 比 1.09
- 振 幅 3.40%
- 歷史最低 0.2589
- 每 手 1
- 風險率 0.77%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Metsera to Present at Goldman Sachs 46th Annual Global Healthcare Conference
<p><p align="left">Metsera Inc.’s CEO, Whit Bernard, will present at the Goldman Sachs 46th Annual Global Healthcare Conference on June 11 at 10:00-10:35 A.M. EDT. The presentation will be available via live webcast and replay on Metsera’s Investors & News page at investors.metsera.com. Metsera is a clinical-stage biopharmaceutical company focused on developing innovative treatments for obesity and metabolic diseases.</p></p>
06-10 11:00
Merus N.V. Announces Proposed Public Offering of Common Shares
Merus N.V. is launching a proposed underwritten public offering of its common shares to advance clinical development, preclinical research, and general corporate purposes. The offering may include an additional 15% of shares. The offering is subject to market and other conditions. Merus plans to use proceeds for its clinical development and research.
06-03 20:05
Mersana Therapeutics Announces Additional Interim Phase 1 Clinical Data For Emiltatug Ledadotin, B7-H4-Directed Dolasynthen ADC
31% confirmed ORR (8 responses in 26 evaluable patients) across B7-H4 high tumors at intermediate doses44% confirmed ORR (7 responses in 16 evaluable patients) in the subset of patients with ≤4 prior lines of
06-02 20:16
Mersana Therapeutics Reports Additional Positive Interim Phase 1 Clinical Data for Emi-Le in Oral Presentation at 2025 ASCO Annual Meeting
Mersana Therapeutics announced interim Phase 1 data for Emi-Le, a B7-H4-targeted ADC, showing a 31% confirmed ORR across B7-H4 high tumors and 44% ORR in patients with ≤4 prior therapies. The drug is being tested in multiple cancers, including triple-negative breast cancer and adenoid cystic carcinoma. No new safety signals were observed, and Emi-Le's safety profile appears differentiated from other ADCs. The company plans to expand trials in TNB...
06-02 12:10
美股大行评级 | 潜在涨幅2840.31%！Mersana Therapeutics获Truist Securities升目标价至10美元，维持"买入"评级
<span> <meta content="no-referrer" name="referrer"></span><p>https://static-hk.hstong.com/public/forum-v2/status/icon/50267976/originalpic/1130419824951111681.png</p><span style="color:#999999;">编者按：每日追踪华尔街最新评级与目标价，挖掘潜力股投资机会。</span><blockquote> <p><span style="color:#fa1432;"><strong>今日重点评级关注</strong></span></p></blockquote><p>• Truist Securities：维持Mersana Therapeutics(MRSN)"买入"评级，目标价从9美元升至10美元</p> <p>• Guggenheim：维持Cabaletta Bio(CABA)"买入
05-17 08:44
Guggenheim Reiterates Buy on Mersana Therapeutics, Maintains $5 Price Target
Guggenheim analyst Michael Schmidt reiterates Mersana Therapeutics (NASDAQ:MRSN) with a Buy and maintains $5 price target.
05-16 23:38
Mersana Therapeutics shares are trading lower after the company reported worse-than-expected Q1 sales results.
Mersana Therapeutics shares are trading lower after the company reported worse-...
05-16 00:58
Mersana Therapeutics Q1 EPS $(0.19), Inline, Sales $2.75M Miss $5.84M Estimate
Mersana Therapeutics (NASDAQ:MRSN) reported quarterly losses of $(0.19) per share which met the analyst consensus estimate. This is a 18.75 percent decrease over losses of $(0.16) per share from the same period last
05-15 19:04
Earnings Scheduled For May 15, 2025
Companies Reporting Before The Bell • Edible Garden (NASDAQ:EDBL) is expected t...
05-15 16:32
An Overview of Mersana Therapeutics's Earnings
Mersana Therapeutics (NASDAQ:MRSN) will release its quarterly earnings report o...
05-15 05:01
